Taken together with other laboratory findings [11, 24, 25], our observed anti-glioma effects of GliPR1 knockdown support that GliPR1 may have potential value as a therapeutic target for this aggressive brain tumor with a poor prognosis. The gene discussed is GLIPR1; the disease is brain neoplasm.